secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001438533-23-000027
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere stockholders approve 2.7M share increase to 2018 equity incentive plan
------------------------------------------------------------------------------

- Stockholders approved amendment increasing authorized shares under 2018 Equity Incentive Plan by 2,700,000 shares.
- Ten directors elected; John Orwin received 50.65M for vs 10.99M withheld.
- Advisory vote on named executive officer compensation passed with 56.25M for, 5.36M against.
- Ernst & Young ratified as independent auditor for FY2023 with 63.81M for, 30K against.
- Plan document filed as Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/0001438533-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000027/tvtx-20230517.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer